TScan Therapeutics (TCRX) Assets Average (2021 - 2026)
TScan Therapeutics (TCRX) posted quarterly Assets Average of $215.4 million for Q1 2026, down 38.79% year-over-year from $351.9 million in Q1 2025, and down 12.27% quarter-over-quarter from $245.5 million in Q4 2025.
TScan Therapeutics (TCRX) Assets Average (2021 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Assets Average for 6 consecutive years, with $215.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 38.79% year-over-year to $215.4 million; the TTM figure through Mar 2026 stood at $215.4 million (down 38.79% YoY), while the FY2025 annual figure was $300.0 million, down 6.74% from the prior year.
- Assets Average retreated to $215.4 million in Q1 2026 per TCRX's latest filing, from $245.5 million in the prior quarter.
- Across five years, Assets Average topped out at $361.4 million in Q3 2024 and bottomed at $158.9 million in Q3 2022.
- Historically, Assets Average has averaged $258.3 million across 5 years, with a median of $256.5 million in 2024.
- Annual changes were most pronounced in 2023 — Assets Average jumped 91.37% — and 2026, when it tumbled 38.79%.
- TScan Therapeutics' Assets Average stood at $182.3 million in 2022, then jumped by 54.58% to $281.8 million in 2023, then grew by 27.61% to $359.6 million in 2024, then plunged by 31.72% to $245.5 million in 2025, then retreated by 12.27% to $215.4 million in 2026.
- Business Quant data shows TCRX's Assets Average at $215.4 million in Q1 2026, $245.5 million in Q4 2025, and $280.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 19.82 Bn |
| 10 | TScan Therapeutics | 101.66 Mn | 101.66 Mn | - | 186.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 186.72 Mn |
| Mar 31, 2026 | 215.39 Mn |
| Dec 31, 2025 | 245.51 Mn |
| Sep 30, 2025 | 280.39 Mn |
| Jun 30, 2025 | 315.64 Mn |
| Mar 31, 2025 | 351.91 Mn |
| Dec 31, 2024 | 359.57 Mn |
| Sep 30, 2024 | 361.45 Mn |
| Jun 30, 2024 | 307.85 Mn |
| Mar 31, 2024 | 256.49 Mn |
| Dec 31, 2023 | 281.76 Mn |
| Sep 30, 2023 | 304.15 Mn |
| Jun 30, 2023 | 245.25 Mn |
| Mar 31, 2023 | 186.33 Mn |
| Dec 31, 2022 | 182.27 Mn |
| Sep 30, 2022 | 158.93 Mn |
| Jun 30, 2022 | 160.31 Mn |
| Mar 31, 2022 | 178.16 Mn |
| Dec 31, 2021 | 196.50 Mn |
| Sep 30, 2021 | 167.45 Mn |